1858 Wealth Management LLC Has $206,000 Stake in Johnson & Johnson $JNJ

1858 Wealth Management LLC decreased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 8.9% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 1,347 shares of the company’s stock after selling 132 shares during the period. 1858 Wealth Management LLC’s holdings in Johnson & Johnson were worth $206,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of JNJ. Nuveen LLC bought a new position in shares of Johnson & Johnson in the 1st quarter worth $1,369,188,000. Bank of New York Mellon Corp lifted its holdings in shares of Johnson & Johnson by 26.4% in the 1st quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company’s stock worth $3,844,580,000 after purchasing an additional 4,842,582 shares in the last quarter. Pacer Advisors Inc. lifted its holdings in shares of Johnson & Johnson by 1,382.0% in the 1st quarter. Pacer Advisors Inc. now owns 3,030,084 shares of the company’s stock worth $502,509,000 after purchasing an additional 2,825,626 shares in the last quarter. Assenagon Asset Management S.A. lifted its holdings in shares of Johnson & Johnson by 159.6% in the 2nd quarter. Assenagon Asset Management S.A. now owns 4,159,260 shares of the company’s stock worth $635,327,000 after purchasing an additional 2,557,388 shares in the last quarter. Finally, Kingstone Capital Partners Texas LLC bought a new position in shares of Johnson & Johnson in the 2nd quarter worth $401,420,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 0.1%

Johnson & Johnson stock opened at $190.88 on Tuesday. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $192.10. The firm has a 50 day moving average price of $178.88 and a 200-day moving average price of $163.97. The company has a market capitalization of $459.71 billion, a P/E ratio of 20.42, a P/E/G ratio of 2.40 and a beta of 0.40. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The business had revenue of $24.02 billion for the quarter. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. As a group, equities analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 55.61%.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. UBS Group set a $198.00 target price on Johnson & Johnson in a report on Friday, October 3rd. Citigroup raised their price objective on Johnson & Johnson from $200.00 to $213.00 and gave the company a “buy” rating in a research note on Tuesday, October 7th. The Goldman Sachs Group raised their price objective on Johnson & Johnson from $186.00 to $212.00 and gave the company a “buy” rating in a research note on Thursday, October 9th. Erste Group Bank upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Wednesday, July 23rd. Finally, Piper Sandler restated an “overweight” rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $192.94.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.16% of the stock is owned by corporate insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.